Smoking may limit immune system’s ability to fight cancer, study shows

pharmafile | February 18, 2019 | News story | Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking 

Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research.

The study of more than 700 melanoma patients in the north of England provides evidence to suggest that smoking may blight the immune system’s response against melanoma which may in turn reduce survival.

The report, led by researchers at the University of Leeds and funded by Cancer Research UK, found that smokers were 40% less likely to survive melanoma than patients who hadn’t smoked within a decade of being diagnosed with the disease.  

Lead author Julia Newton-Bishop, professor of dermatology at the University of Leeds, said: “The immune system is like an orchestra, with multiple pieces. This research suggests that smoking might disrupt how it works together in tune, allowing the musicians to continue playing but possibly in a more disorganised way.”

“The result is that smokers could still mount an immune response to try and destroy the melanoma, but it appears to have been less effective than in never-smokers, and smokers were less likely to survive their cancer. Based on these findings, stopping smoking should be strongly recommended for people diagnosed with melanoma.”

Dr Julie Sharp, head of health information at Cancer Research UK, said: “Overall, these results show that smoking could limit the chances of melanoma patients’ survival so it’s especially important that they are given all the support possible to give up smoking for good.”

Louis Goss

Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Latest content